Stock Information

Advicenne shares were listed on Euronext Paris on December 6, 2017.

ISIN code: FR0013296746

Ticker: ADVIC

Number of outstanding shares: 8 062 344
Eligible for PEA and PEA-PME

Click here for live stock price.

Analyst Coverage

Gilbert Dupont : Guillaume Cuvillier, Jamila El Bougrini
NIBC : Dylan van Haaften, Anita Ye

Ownership Structure on January 5, 2018

Analyst Coverage of ADVIC (Contact Details)

 

Rx Securities

Dr. Samir Devani

Managing Director,
Rx Securities
1 Fore Street Avenue
Moorgate
London EC2Y 9DT
+44 207 993 8210 (direct)
+44 7717787460 (mobile)

Gilbert Dupont

Jamila El Bougrini, Ph.D., M.B.A.

Equity Research Analyst
Lifescience GILBERT DUPONT
Tel. +33 (0)1 40 22 55 88
Mob. +33 (0)6 25 97 88 21
jamila.elbougrini@gilbertdupont.fr
www.gilbertdupont.fr

NIBC

Dylan van Haaften & Anita Ye

NIBC Bank N.V.
Research | Life Sciences
M: +31 (0)6 11 91 54 85
E:  dylan.van.haaften@nibc.com
Mobile: +31 (0)62 116 17 87
Email: anita.ye@nibc.com

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

7 + 3 =

© 2019 Advicenne